American Bio Medica's oxycodone assay gains US nod:
This article was originally published in Clinica
Executive Summary
American Bio Medica Corporation has received US FDA 510(k) clearance for what it claims is the first on-site, point-of-care test for oxycodone, a synthetic opiate found in commonly abused prescription painkillers, including OxyContin. The Rapid One OXY assay is a urine-based test that can provide results within minutes. It is designed to detect oxycodone at a very low level and does not detect other opiates at this level, says the Kinderhook, New York firm.
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.